Research programme: sublingual parathyroid hormone 1-34 - Albireo Pharma
Alternative Names: teriparatide sublingual; VIAmassLatest Information Update: 06 Mar 2023
At a glance
- Originator Biodel
- Class Peptide hormones
- Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor type 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 02 Mar 2023 Albireo Pharma has been acquired by Ipsen
- 09 Nov 2010 Development discontinued for Osteoporosis before 2009
- 13 Jul 2007 Preclinical trials in Osteoporosis in USA (Sublingual)